Continue your hepatology and liver-related disease education though our multi-disciplinary, open access eLearning platform EASL Campus. Sign up to access state-of-the-art digital courses and resources...

Loss of Bsep/Abcb11 results in a hydrophilic bile acid (BA) pool consisting of tetrahydroxylated BAs (THBAs) reducing cholestasis-induced liver injury. In this study, we investigated whether loss of B...

Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.

Nature Reviews Gastroenterology & Hepatology, Published online: 29 September 2025; doi:10.1038/s41575-025-01107-2Portal hypertension and systemic inflammation are key factors driving decompensation and organ failure in cirrhosis. This Review examines those two factors and, based on their mechanistic interaction, proposes a new concept of the clinical phenotypes in decompensated cirrhosis.

There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....

Previous studies suggested that anticoagulation decreases the probability of developing portal hypertension (PHT)-related complications and improves survival in cirrhotic patients. Our study aimed to ...